Skip to main content
HR 1839 118th Congress House Crime and Law Enforcement Congressional oversight Criminal procedure and sentencing Drug trafficking and controlled substances Manufacturing Retail and wholesale trades Veterinary medicine and animal diseases

Combating Illicit Xylazine Act

Introduced: April 26, 2023 Introduced by: Panetta, Jimmy Democratic · California See on congress.gov
This bill died when the 118th Congress ended
It never became law before the 118th Congress (2023–2024) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Apr 7, 2023
Referred to the Subcommittee on Health.
Mar 28, 2023
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Mar 28, 2023
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Combating Illicit Xylazine Act

This bill criminalizes the illicit use of xylazine. (Xylazine, also known as Tranq, is a sedative that is approved for use in animals. The Drug Enforcement Administration (DEA) has reported an increase in the trafficking of fentanyl mixed with xylazine.)

Specifically, the bill establishes criminal penalties for manufacturing, distributing, or dispensing, or possessing with intent to manufacture, distribute, or dispense, xylazine for illicit use (i.e., for use in humans) in accordance with the penalties for schedule III substances (up to 10 years imprisonment or, if death or serious bodily injury occurs, up to 15 years imprisonment, as well as criminal fines).

In addition, the DEA must coordinate with the Food and Drug Administration to report on the prevalence of the illicit use of xylazine, including associated supply chains. The bill also declares the illicit use of xylazine as an emerging drug threat.

What's happening now April 7, 2023

Referred to the Subcommittee on Health.

 Related & companion bills 1
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 3
 Cosponsors 100
Pence, Greg
· Nov 21, 2024
R
Fong, Vince
California · Jul 10, 2024
R
Lawler, Michael
New York · May 31, 2024
R
Guthrie, Brett
Kentucky · Mar 6, 2024
D
DeSaulnier, Mark
California · Jan 30, 2024
D
Torres, Norma J.
California · Dec 11, 2023
R
Malliotakis, Nicole
New York · Sep 27, 2023
R
De La Cruz, Monica
Texas · Sep 22, 2023
D
DelBene, Suzan K.
Washington · Sep 5, 2023
D
Deluzio, Christopher R.
Pennsylvania · Sep 5, 2023
D
Plaskett, Stacey E.
Virgin Islands · Sep 5, 2023
D
Schneider, Bradley Scott
Illinois · Sep 5, 2023
R
Simpson, Michael K.
Idaho · Jul 11, 2023
R
Weber, Randy K. Sr.
Texas · Jun 21, 2023
D
Sorensen, Eric
Illinois · Jun 14, 2023
D
Magaziner, Seth
Rhode Island · Jun 13, 2023
Cartwright, Matt
· Jun 12, 2023
D
Garamendi, John
California · Jun 12, 2023
R
Steil, Bryan
Wisconsin · Jun 12, 2023
D
Courtney, Joe
Connecticut · Jun 7, 2023
D
Strickland, Marilyn
Washington · Jun 7, 2023
D
Cuellar, Henry
Texas · Jun 6, 2023
D
McCollum, Betty
Minnesota · Jun 6, 2023
D
Moskowitz, Jared
Florida · Jun 6, 2023
D
Dingell, Debbie
Michigan · Jun 1, 2023
D
Soto, Darren
Florida · Jun 1, 2023
D
Keating, William R.
Massachusetts · May 30, 2023
D
Sánchez, Linda T.
California · May 30, 2023
R
Balderson, Troy
Ohio · May 25, 2023
R
Johnson, Dusty
South Dakota · May 25, 2023
R
Miller-Meeks, Mariannette
Iowa · May 25, 2023
D
Costa, Jim
California · May 24, 2023
R
Hunt, Wesley
Texas · May 23, 2023
D
Ivey, Glenn
Maryland · May 23, 2023
R
Nehls, Troy E.
Texas · May 23, 2023
D
Pettersen, Brittany
Colorado · May 23, 2023
R
Banks, Jim
Indiana · May 22, 2023
D
Davids, Sharice
Kansas · May 22, 2023
R
Dunn, Neal P.
Florida · May 22, 2023
D
Huffman, Jared
California · May 22, 2023
R
Obernolte, Jay
California · May 22, 2023
R
Bice, Stephanie I.
Oklahoma · May 17, 2023
D
Barragán, Nanette Diaz
California · May 15, 2023
R
Moran, Nathaniel
Texas · May 15, 2023
R
Carey, Mike
Ohio · May 11, 2023
D
Gottheimer, Josh
New Jersey · May 11, 2023
R
Hudson, Richard
North Carolina · May 11, 2023
D
Kelly, Robin L.
Illinois · May 11, 2023
D
Schrier, Kim
Washington · May 11, 2023
R
Smith, Christopher H.
New Jersey · May 11, 2023
Page 1 of 2 Next
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 1839: Combating Illicit Xylazine Act. 118th Congress. Open America. https://openamerica.io/bill/118-HR-1839/
MLA
"H.R. 1839: Combating Illicit Xylazine Act." 118th Congress, 2026, Open America, https://openamerica.io/bill/118-HR-1839/.
Bluebook (legal)
H.R. 1839, 118th Cong. (2026), https://openamerica.io/bill/118-HR-1839/.
Markdown link
[H.R. 1839: Combating Illicit Xylazine Act](https://openamerica.io/bill/118-HR-1839/)
Report a problem